Tuesday, 23 June 2020

International Epilepsy Diagnosis & Treatment Market 2019 Estimation And Forecasts Up To 2023

Increasing prevalence of epilepsy, rising number of traumatic brain injury cases, growing geriatric population, and rising healthcare expenditures are the major drivers for the global epilepsy diagnosis and treatment market trends. However, high cost of therapeutic surgeries, low per capita healthcare expenditure, and lack of awareness for the disease in emerging economies are estimated to restrain the market growth during the projected period. The global epilepsy diagnosis and treatment market is estimated to grow at an approximate CAGR of 6.3% during the forecast period.
Segmentation
The global epilepsy diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, and end-user. On the basis of type, the market is segmented into idiopathic, cryptogenic, symptomatic, and others. On the basis of diagnosis, the market is segmented into neurological exam, blood test, imaging, and others. The imaging segment is sub-segmented into electroencephalogram, computerized tomography, magnetic resonance imaging, positron emission tomography, and others. On the basis of treatment, the market is segmented into medication, surgery, brain stimulation, and others. The medication segment is sub-segmented into acetazolamide, carbamazepine, clobazam, and others. The surgery segment is sub-segmented into hemispherectomy, corpus callosotomy, resection surgery, and others. The brain stimulation segment is sub-segmented into deep brain stimulation, responsive neurostimulation, and others. On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
Regional Analysis
The Americas dominate the global epilepsy diagnosis and treatment market, which can be attributed to the presence of a well-developed healthcare sector and huge patient population within the region. Moreover, increasing number of head trauma cases boosts the American market. Europe holds the second largest market share owing to the availability of funds for research, presence of a well-developed healthcare sector, and government support. Followed by Europe, the Asia Pacific region is projected to be the fastest growing region for the global epilepsy diagnosis and treatment market. Presence of developing healthcare sector, along with emerging economies of the Asia Pacific region boosts the market growth. The Middle East & Africa has the least share in the global epilepsy diagnosis and treatment market, owing to the low per capita healthcare expenditures, lack of awareness for the disease, and stringent government policies, especially in the African region. On the other hand, the Middle East region within the Middle East & Africa is estimated to be fastest growing region due to growing healthcare expenditures and presence of the developed economies, such as Kuwait, Qatar, Dubai, and others.
Key Players
The key players for the global epilepsy diagnosis and treatment market are Pfizer, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), UCB Pharma Ltd. (U.K), Abbott (U.S.), GlaxoSmithKline plc (U.K), Novartis International AG (Switzerland), Sanofi S.A. (France), Shire (Republic of Ireland), Medtronic (U.S.), NeuroWave Systems Inc. (U.S.), Natus Medical Incorporated. (U.S.), Siemens Ltd. (Germany), and others.

Worldwide Hyperspectral Imaging System Market Segmentation And Analysis By Recent Trends And Growth Prospects By Regions To 2025

Market Highlights
According to MRFR analysis, Global Hyperspectral Imaging System Market is expected to register a CAGR of 17.4% during the forecast period of 2019 to 2025 and held a value of USD 10,700 Million in 2018.
Hyperspectral imaging system has wide applications in areas such as art conservation, vegetation, water resource control, archaeology, food quality, forensic medicine, crime scene detection, and forensic medicine. HSI technology is mainly used by the defense sector, government agencies, and non-military application sectors such as agriculture and mineral.
The growth of the global hyperspectral imaging system market is boosted by various factors such as the growing industrial applications of hyperspectral imaging,  Technological advancements in electronics industry, such as sensor design, high spectral resolution, high spatial resolution, compact and lightweight devices, growing prevalence of cancer, and increasing awareness of innovative diagnostics methods.
Additionally, the introduction of innovative products in the market is expected to drive the growth of the market during the forecast period. For instance, In January 2020, Specim, Spectral Imaging Ltd. (Finland), launched Specim’s new AFX10, a compact hyperspectral camera for airborne use. Specim’s new AFX10 is easy to use and can be used to check water quality, estimating the fertilizing need in agriculture, identifying vegetation species, or studying wildlife population
However, the high cost associated with the use of hyperspectral imaging and scarcity of qualified professionals is likely to hamper the growth of the market during the forecast period.
Several market players currently dominate the global hyperspectral imaging system market. The key players are engaged in product launches and strategic collaborations to strengthen their market positions.
Regional Analysis
The Market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas held the maximum share in the year 2018, owing to the presence of established key players in countries such as the US and Canada. The hyperspectral imaging system market in the Americas has further been categorized into North America and Latin America, with the North American market further divided into the US and Canada. The European hyperspectral imaging system market has been categorized as Western Europe and Eastern Europe. The Western European market has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The hyperspectral imaging system market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hyperspectral imaging system market in this region is anticipated to be the fastest growing during the assessment period due to the rising mining activities, and blooming healthcare, agriculture, and biotechnology sector in the region. The hyperspectral imaging system market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Hyperspectral Imaging System Market has been segmented based on Product, Technology, and Application.
The market, based on product, has been divided into visible/near-infrared (VNIR), short-wave infrared (SWIR), mid-wave infrared (MWIR), long-wave infrared (LWIR). The Visible/Near-Infrared (VNIR) systems segment is likely to be the largest due to the high adoption of visible/near-infrared (VNIR) systems in various industries. The mid-wave infrared (MWIR) segment is predicted to be the fastest-growing due to increasing awareness about the rising adoption of MWIR systems in detecting volcanic vents, industrial gas leaks, or biomass burning events.
The global hyperspectral imaging system market has been segmented, based on the technology, into push broom, snapshot, and others. The push broom segment is anticipated to be the largest segment during the forecast period due to the rising popularity of these devices owing to the simplified illumination requirements, minimized illumination exposure, high spectral resolution, and heat load, and the shorter capturing time.
The applications segment of the global hyperspectral imaging system market surveillance, remote sensing, machine vision/optical, and medical diagnostics. The surveillance segment is likely to hold the maximum share during the forecast period due to the rising adoption of innovative technologies in the defense sector.
Key Players
Some of the Key Players in the Global Hyperspectral Imaging System Market are Headwall Photonics, Inc. (the US), Specim, Spectral Imaging Ltd. (Finland), Norsk Elektro Optikk as (NEO) (Norway), Resonon, Inc. (the US), Corning Incorporated(US), Telops (Canada), Applied Spectral Imaging(US), Bayspec, Inc.(the US), Surface Optics Corporation (US), Chemimage Corporation (US), Cubert GmbH (Germany), Raytheon (US), Galileo Group, Inc.(the US), Hypermed Imaging, Inc.(the US), Inno-Spec (Germany), Camlin Group Ltd. (UK), IMEC (Belgium), XIMEA GmbH (Germany), among others.

Worldwide Verrucous Carcinoma Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2023

Market Insights
Verrucous Carcinoma typically debuts as an anomalous growth or as alteration in the constancy of an earlier potentially malignant ailment of the oral cavity. Verrucous Carcinoma is a rare, locally aggressive, clinically exophytic, low-grade, slow-growing, well-differentiated squamous cell carcinoma with nominal metastatic potential. It is unusual subtype of malignant ailment which affects oral cavity. Verrucous Carcinoma can affect all mucosal sites of the oral cavity. However, the frequency of malignant transformation of a leukoplakia to an OVC is considerably higher if they are in the gums in comparison to the tongue.
Verrucous Carcinoma is mainly caused by the snuffing of tobacco or chewing of tobacco. It is also referred to as snuff dipper's cancer. Verrucous Carcinoma mostly prevails at oral zones. The condition common in males within the age group 50 to 80 years. The increasing incidences of oral cancer primarily influences the market. Lifestyle factors such as smoking marijuana or tobacco and alcohol consumption mostly drives the Verrucous Carcinoma market. Additionally, growing consumption of alcohol, increasing adoption of sedentary lifestyle, increasing rates of sexually transmitted viruses by human papillomavirus, and family history of cancer prevalence contribute largely towards the development of the market. In 2015, the World Health Organization reported that 1.1 billion people smoked tobacco globally. This is likely to accelerate the market growth over the forecast period.
However, the high cost of surgical procedures, side effects associated with treatments, and expensive chemotherapy treatments are anticipated to limit the market growth to a certain extent.
Market Segmentation
The worldwide Verrucous Carcinoma market has been segmented based on treatment, end-user, and diagnosis.
Based on treatment, the Verrucous Carcinoma market has been segmented into radiation therapy, surgery, targeted drug therapy, and chemotherapy. Surgery has been sub-segmented into Mohs micrographic surgery and surgical excision. Chemotherapy has been sub-segmented into 5-fluorouracil, bleomycin, methotrexate, cisplatin, and others. Based on end-user, the Verrucous Carcinoma market has been segmented into ambulatory surgical centers, hospitals and clinics, research centers, diagnostic centers, and others. Based on diagnosis, the Verrucous Carcinoma market has been segmented into endoscopy, imaging tests, and biopsy. Imaging tests have been sub-segmented into magnetic resonance imaging, positron emission tomography scans, and computerized tomography scans.
Regional Analysis
The Americas represent the largest Verrucous Carcinoma market share in the global market. The market growth is owing to the increasing healthcare expenditure and surging prevalence of Human Papillomavirus (HPV). As recorded by the Genital HPV Infection, Fact Sheet 2017, 79 million American adults were infested with HPV. Europe (Belgium, UK, Netherlands, and France) represents the second largest Verrucous Carcinoma market over the forecast period. Rising prevalence of head and neck cancer drives the Verrucous Carcinoma market in this region. The Cancer Research UK revealed that in 2015, there were12061 new instances of neck and head cancer. These statistics substantially drive the Verrucous Carcinoma market in Europe.
In 2017, Asia-Pacific was estimated to be the fastest growing region for the worldwide Verrucous Carcinoma market. The market has been expected to develop owing to the rising addiction to smoking. According to the World Health Organization, in 2015, 33.7% and 47.6% of people smoked tobacco in Japan and China, respectively. The Middle East and Africa holds the least market share due to lack of availability of trained healthcare professionals and low per capita income in the region. Nevertheless, the growing palliative and oncology care services both at the community and the hospital level are expected to influence the market positively.
Key Players
The global Verrucous Carcinoma market is dominated by key players such as Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Bristol-Myers Squibb Company (US), Eli Lilly and Company. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Europe), Pfizer Inc. (US), Novartis AG (Europe), and others.

Colposcopy Market Value Chain, Factor Analysis, Region And Forecasts Till 2023

Market Scenario
A colposcope is basically a surgical instrument similar to an electric microscope with a source of light that allows gynecologists to examine the vagina and cervix more clearly and under proper magnification. The rising prevalence of cervical cancer around the globe is the primary factor driving the growth of the colposcopy market.
For instance, according to the World Health Organization (WHO) in 2017, cervical cancer is the second most reason for the death of women worldwide. Currently, awareness programmes are conducted by numerous NGOs focusing on health-related issues in women such as cervical cancer which will increase the demand for colposcopes.
The upcoming Global Colposcopy Market trends is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global colposcopy market is expected to register a CAGR of ~6.8% during the forecast period, 2018–2023.
Despite these drivers, factors such as high installation cost of this device and lack of skilled clinical users to operate colposcopes are likely to restrain the growth of the market.
Company Profiles            
  • Carl Zeiss
  • Olympus Corporation
  • Danaher Corporation
  • Philips Healthcare
  • CooperSurgical
  • McKesson Corporation
  • DYSIS Medical
  • Atmos
  • Alliton
  • Seliga Microscopes
  • Karl Kaps
  • Bovie Medical
Segmentation
The global colposcopy market is segmented on the basis of instrument type, instrument portability, application, and end-users.
On the basis of instrument type, the market is classified into optical colposcopes and digital colposcopes.
On the basis of instrument portability, the market is classified into portable, fixed, and handheld.
On the basis of application, the market is classified as cervical cancer screening, physical examinations, and others.
On the basis of magnification type, the market is classified into fixed magnification and variable magnification
On the basis of end-user, the market is classified into hospitals, clinics, diagnostic centers, and others.
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American colposcopy market is further segmented into North America and South America. North America is further classified as the US and Canada.
The European colposcopy market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. 
The colposcopy market in Asia-Pacific is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia-Pacific.
The Middle Eastern and African colposcopy market is segmented into the Middle East and Africa.
Regional Market Summary
Asia-Pacific is the fastest growing region in the market owing to the increasing cases of cervical cancer in the region, growing demand for cervical cancer screening, and rising healthcare expenditure in Asian countries. Additionally, according to a study published in the World Health Organization (WHO) in 2017, every year cervical cancer kills more than 250000 women, and 85% of these deaths occur in low- and middle-income countries. Furthermore, the rapid development of economies and increasing healthcare expenditure have fuelled the growth of the market.
The Americas is likely to dominate the global colposcopy market share owing to technological advancements in colposcopes such as high-quality video and improved accuracy in detection. For instance, the American Cancer Society in 2018, estimated about 13,240 new cases of invasive cervical cancer to be diagnosed in the US with nearly 4,170 women dying from cervical cancer. Furthermore, continuous development of advanced colposcopy by manufacturers in the region contributes to the market growth.
Europe is likely to hold the second position in the global colposcopy market. It is expected that the favorable reimbursement scenario is responsible for the ambient growth in this region. Additionally, according to the Cancer Research UK in 2017, more than 3000 new cases of cervical cancer are diagnosed in the UK each year.  
The Middle East and Africa accounts for the lowest market share in the global colposcopy market owing to the lack of awareness regarding cervical cancer in the MEA region.

Electronic Pill Market 2023 Forecasts By Global Industry Analysis In 2019 Report

Market Scenario
Electronic pills are equipped with sensors and cameras which allow capturing of several images of the gastrointestinal tract. They are used for diagnostic purposes and are increasingly replacing traditional diagnostic methods. It further monitors various parameters such as temperature, conductivity, pH, and dissolved oxygen. Market Research Future (MRFR) has thoroughly studied the trends and patterns governing the global electronic pills market over the forecast period of 2018-2023 in a detailed study. MRFR projects a CAGR of 15% within the electronic pills market over the forecast period.
Towering prevalence of gastrointestinal disorders has driven the market for electronic pills. Electronic pills alleviate tedious and painful diagnostic procedures such as colonoscopy and endoscopy and provide accurate results without much discomfort to the patient. Surging cases of stomach cancer coupled with increasing preference for minimally invasive medical procedures is likely to augment the growth of the electronic pills market. Healthcare professionals are increasingly adopting theses pills as they facilitate on-site diagnosis. Other factors which contribute to the growth of the market include improving reimbursement scenario and rise in global geriatric population who are more susceptible to various chronic diseases. Additionally, capsule endoscopy has gained widespread adoption as a non-invasive diagnostic method which is likely to fuel the growth of the market over the forecast period with new Electronic Pill Market Technology. On the contrary, the growth of the electronic pills market size can be impeded by factors such as lack of awareness, capsule retention, and bowel obstruction. Moreover, high costs aligned with electronic pills and regulatory restrictions are anticipated to hinder the growth of the market.
Segmentation
The global electronic pill market has been segmented based on application, target area, part, and end user.
By application, the electronic pill market has been segmented into capsule endoscopy, drug delivery, and patient monitoring.
By target area, the electronic pill market has been segmented into oesophagus, stomach, small intestine, and large intestine.
By part, the electronic pill market has been segmented into biocompatible capsule encasing microsensors, control chip, radio transmitter and power source.
By end user, the electronic pill market has been segmented into Hospitals, diagnostic centers, clinical research organizations, and medical centers.
Regional Analysis
By region, the electronic pill market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).
In 2017, the global electronic pill market was led by the Americas. The dominance of the Americas market can be attributed to the surging prevalence of gastrointestinal diseases, vigorous R&D activities and fast uptake of the latest technologies in the region.
Europe follows the Americas closely and is estimated to showcase substantial growth over the forecast period. Escalating cases of gastric cancer and high demand for diagnostics services is fuelling the growth of the market.
The APAC electronic market is likely to witness the fastest growth over the forecast period. The growth of the market can be attributed to increasing patient population, growing medical tourism in the region, and extensive R&D activities and high investment by the governments in the region create a conducive environment for the growth of the market.
The MEA market accounts for the least share of the electronic pill market. The growth of the market might be restrained by stringent government policies and poor economic conditions.
Competitive Landscape
Medtronic, JINSHAN Science & Technology, Medimetrics (Mexico), Medisafe, CapsoVision, Inc. (US), Given Imaging Ltd. (Israel), (Bio-Images Drug Delivery) BDD LTD (UK), Proteus Digital Health (US), Olympus Corporation, and INTROMEDIC are the distinguished players in the electronic pill market.
Industry Updates
February 2019 - a new electronic pill equipped with Wi-Fi transmitter has been developed which is capable of harvesting energy from inside a patient's stomach and record core body temperature and then send data to an external monitor.

Worldwide Overactive Bladder Treatment Market Booming Industry Size And Revenue | Future Vision Footbridge 2023 In Healthcare Sector

Market Scenario:
Overactive bladder is a condition that occurs in various diseases such as Parkinson's disease, multiple sclerosis, stroke, and others. Rise in prevalence of these diseases and rapid increase in the global geriatric population are inducing high demand for effective treatment of overactive bladder, which in turn is propelling the growth of the global overactive bladder treatment market. Increased marketing activities, availability of affordable treatments and development of innovative treatment procedures are also fueling the growth of the global overactive bladder treatment market. However, low penetration of treatment options in the healthcare sector and lack of awareness among the population of the underdeveloped countries are restricting the expansion of the global overactive bladder treatment market size during the assessment period.
The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market growth is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.
Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.
Company Profiles    
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical
  • Allergan, Plc. 
  • Mylan N.V. 
  • Endo International Plc 
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sanofi S. A.
  • Aurobindo Pharma Limited 
  • Johnson & Johnson
  • Intas Pharmaceuticals Ltd. 
  • Apotex Inc. 
  • Macleods Pharmaceuticals Ltd. 
  • Medtronic PLC
  • Cogentix Medical, Inc.
  • Others
Segmentation
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.
On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.
Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.
The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.
The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.
Regional Market Summary
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.

Worldwide Optical Imaging Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2023

Market Scenario
Optical imaging has the ability to improve point of care in the healthcare setting since it provides improved screening and detection of disease. The global optimal imaging market growth is anticipated to attain a valuation of USD 1.92 Bn at a CAGR of 10% over the forecast period of 2018-2023, projects Market Research Future (MRFR) in an extensive study.
Some of the Top Key Players in Optical Imaging Market are Jude Medical, Inc., Carl Zeiss Meditec AG, Bioptigen, Inc., Canon Inc, Heidelberg Engineering, Inc., Topcon Corporation, Perkinelmer, Inc., Koninklijke Philips N.V. and Agfa-Gevaert N.V. etc.
Driven by critical healthcare needs, optimal imaging is gaining traction as a detector technology. Optimal imaging is a technique where cellular and molecular function in a living body is interrogated with the help of light and the special properties of photons to obtain detailed images of organs and tissues.
Optical imaging is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of optical imaging techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market.
However, factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for optical imaging procedures restrict market growth.
Segmentation
The global optical imaging market is segmented on the basis of products, techniques, therapeutic area, application, and end-user. Considering the type of product, the market is segmented into imaging systems, software, lenses, illumination systems, cameras and others. Imaging systems are further segmented into optical imaging systems and spectral imaging systems. On the basis of technique, the market is segmented into Optical Coherence Tomography (OCT), photoacoustic imaging, diffused optical tomography, hyperspectral imaging, near-infrared spectroscopy, and super-resolution microscopy.
On a therapeutic area basis, it is segmented into neurology, oncology, ophthalmology, dentistry, cardiology, dermatology, and others. On account of application, the market is segmented into pre-clinical and clinical research, pathological imaging and intraoperative imaging. According to the end-user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies. Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Market Summary
In terms of geography, Americas dominates the market for optical imaging owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders about rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems and presence of pharmaceutical giants key players also propel the market growth in this region. For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Thus, this huge patient pool is going to boost up the market growth during the forecast period.
Europe is the second largest market and holds a healthy place in global optical imaging market share due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of optical imaging over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.
Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the department of neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period.  Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in optical imaging market in future.